Mineralys Therapeutics presents new Lorundrostat Launch-HTN data
New analyses from the Launch-HTN trial reported that 46% of participants on lorundrostat 50 mg achieved the AHA/ACC systolic BP target (<130 mmHg) at 12 weeks.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.